Still Bullish On HCV, Idenix Also Plans To Focus On Oncology, Other Infectious Diseases
This article was originally published in The Pink Sheet Daily
Executive Summary
New Chief Scientific Officer Jacques Dumas says the clinical-stage firm intends to leverage its expertise in nucleoside discovery to create drug candidates for cancer and other infectious diseases. Concurrent with its drug development in hepatitis C, Idenix plans to address these other indications with the help of partners.